共 50 条
- [41] HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical modelsScientific Reports, 13Hang KeFaming ZhangJingjing WangLingxin XiongXiaoyu AnXiaolong TuCen ChenYueying WangBinchen MaoSheng GuoCunxiang JuXiangfei HeRuilin SunLei ZhangOwen A. O’ConnorQi-Xiang Li
- [42] Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trialsEXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (03) : 229 - 242Kiem, DominikOcker, MatthiasGreil, RichardNeureiter, DanielMelchardt, Thomas
- [43] Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity (vol 10, 575737, 2020)FRONTIERS IN ONCOLOGY, 2021, 11Sam, JohannesColombetti, SaraFauti, TanjaRoller, AndreasBiehl, MarleneFahrni, LindaNicolini, ValeriaPerro, MarioNayak, TapanBommer, EstherSchoenle, AnneKaragianni, MariaLe Clech, MarineSteinhoff, NathalieKlein, ChristianUmana, PabloBacac, Marina
- [44] A PD-L1 x CD3 bispecific antibody enhances the anti-tumor efficacy of regorafenib in pre-clinical colon cancer modelsCANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)Okpalanwaka, Izuchukwu F.Daugherity, Elizabeth A.McCormick, Amanda L.Anderson, Trevor S.Smith, Savanna L.Lawrence, CarynLowe, Devin B.
- [45] B7-H3 & PD-L1 double-humanized BALB/c mouse: a novel animal model for preclinical studies of human B7-H3 antibodies or bispecific antibodiesCANCER RESEARCH, 2023, 83 (07)Guo, ShiyingSong, LingyuQin, XinXu, JianmingSun, HongyanJu, CunxiangWang, HongyuChen, Santi SuryaniLi, ZhiyingMoore, Mark WadeZhao, JingGao, Xiang
- [46] MB101, a novel PD-L1 x CD3 targeted bispecific antibody, exhibits potent tumor-killing efficacy with minimal off-tumor toxicityCANCER RESEARCH, 2023, 83 (07)Kim, SunaBang, HyojooJung, YongjunCho, SunjungKim, YoungsamPark, Sang-hyunKang, Seok ChanPark, YoungjinJung, Sungyoub
- [47] Correlation of decreased expression of PD-L1 on circulating tumor cells and clinical benefit in SCLC Patients treated with RRx-001, a CD47 downregulator, in a phase II trial.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Carter, CoreyTomita, YusukeYuno, AkiraBaker, JonathanLee, Min-JungLee, SunminCaroen, ScottQuinn, Mary FlanaganOronsky, BryanReid, Tony R.Cabrales, PedroAbrouk, NacerTrepel, Jane B.
- [48] In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefitTRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 274 - 278Tomita, YusukeOronsky, BryanAbrouk, NacerCabrales, PedroReid, Tony R.Lee, Min-JungYuno, AkiraBaker, JonathanLee, SunminTrepel, Jane B.
- [49] INCREASED CD11B+-CD49B+NATURAL KILLER (NK) CELL TUMOR INFILTRATION AFTER CO-ADMINISTRATION OF ANTI-PD-1/PD-L1 ANTIBODIES IN A MURINE NEUROBLASTOMA MODELPEDIATRIC BLOOD & CANCER, 2022, 69 : S218 - S218Inoue, SeiichiroHoriuchi, YutakaTakeuchi, YutaMurakami, TakashiOdaka, Akio
- [50] Efficacy and pharmacodynamic effect of anti-CD73 / PD-L1 monoclonal antibodies in combination with chemotherapy: Observations from mouse tumor models.CANCER RESEARCH, 2021, 81 (13)Eyles, JimWatkins, AmandaIlieva, KristinaMullins, StefAnderton, JudeGalvani, ElenaGarcon, FabienRyan, KelliKaistha, Brajesh P.Dannhorn, AndreasLing, StephanieSlidel, TimKar, GozdeSchuller, AlwinCooper, Zachary A.Sachsenmeier, KrisLuheshi, NadiaKumar, RakeshWilkinson, Robert W.